• image

    There's no insulin

    like your own

  • image

    Job opportunities

    at Diamyd Medical

Notification of attendance at the annual general meeting

The shareholders of Diamyd Medical AB (publ) are hereby summoned to the Annual General Meeting at 15:00 pm. on Thursday, December 3, 2026.

 

Calendar

 Dates for financial information and other events
Data pager
Data pager
12
December 3, 2026
Annual General Meeting
Annual General Meeting 2026
January 26, 2027
Interim report Q1
Interim report Q1 2026/27
March 24, 2027
10th ASIT Summit, Boston, USA
April 27, 2027
Interim report Q2
Interim report Q2 2026/27
June 29, 2027
Interim report Q3
Interim report Q3 2026/27
A facility for manufacturing of biological products has been established in Umeå, the Capital of Västerbotten County in Sweden. The primary purpose is the manufacture of recombinant GAD65, the active pharmaceutical ingredient retogatein in an investigational drug for the treatment of type 1 diabetes.

The long-term objective for the facility is to support potential commercial-scale production of retogatein (rhGAD65). The facility also serves as a strategic hub for the manufacturing of biological substances for additional therapeutic programs.

THE COMPANY

Diamyd Medical develops precision medicine therapies to prevent and treat type 1 diabetes.
The share is traded on Nasdaq First North Growth Market (ticker: DMYD B).


Read More
  • Type 1 diabetes is a chronic progressive autoimmune disease where the immune system attacks and breaks down the insulin-producing cells in the pancreas. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 %.

  • Retogatein (rhGAD65/alum) is an investigational antigen-specific immunotherapy for the prevention and treatment of type 1 diabetes. Retogatein is under development for individuals with type 1 diabetes carrying the genetic HLA DR3-DQ2 haplotype.

Order GAD for preclinical research

Corporate Website Disclaimer
This website is intended for informational purposes only and is designed to provide corporate and investor-related information about Diamyd Medical globally. It is not intended for promotional purposes or to provide medical or healthcare advice.
GAD PRODUCTS